Trial Success Sets Up Roche’s Alecensa To Be First ALK+ Drug In Adjuvant NSCLC

Will Help Sustain Class Leadership

 
• By Andrew McConaghie
  
Roche
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas